This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Neuroleptic malignant syndrome

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

Malignant neuroleptic syndrome is a rare, potentially fatal idiosyncratic reaction occurring in response to neuroleptic drug therapy. It has been reported for haloperidol, chlorpromazine and flupenthixol decanoate.

The syndrome lasts 5-10 days after the discontinuation of drug therapy during which time ITU support is necessary (1)

There is no proven treatment though bromocriptine and dantrolene have been used.

This syndrome can also occur in patients with Parkinson's disease following withdrawal of levodopa or dopamine antagonists or by the addition of lithium (2).


  • (1) BMJ editorial (1993). How "malignant" is the neuroleptic malignant syndrome.BMJ, 307, 1223-4.
  • (2) Prescriber (2001), 12 (5), 43-8.

Related pages

Create an account to add page annotations

Add information to this page that would be handy to have on hand during a consultation, such as a web address or phone number. This information will always be displayed when you visit this page

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.


Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.